Summary Angelica keiskei (Ashitaba) is a perennial plant belonging to the Umbelliferae family. Recently, much attention has been focused on Ashitaba products as a so-called health food for the breakdown of cellulite among various physiological benefits of Ashitaba. The current study was carried out to investigate the physiological efficacy of dietary Ashitaba on serum and liver lipid profiles and body fat accumulation in rats. Rats were fed a high-fat diet with various amounts of Ashitaba for 28 d. Perirenal adipose tissue weights of rats fed the ϫ 10 (170 mg/100 g BW) Ashitaba diet were significantly higher ( p Ͻ 0.05) than those of the control group. Serum triacylglycerol concentrations of rats fed the ϫ 100 (1,700 mg/100 g BW) Ashitaba diet were significantly higher ( p Ͻ 0.05) than those of the ϫ 1 (17 mg/100 g BW) group. Fecal weights and bile acid excretions of rats fed the ϫ 10 or ϫ 100 Ashitaba diet were significantly higher ( p Ͻ 0.05) than those of the control group. However, there were no significant differences in the body weight gain, epididymal adipose tissue weight, serum cholesterol or liver lipid concentrations or other biochemical profiles in the serum. Furthermore, even the excessive ingestion of Ashitaba had no significant pathological impact on the liver or kidney. These results indicate that the large intake of Ashitaba products may supply dietary fiber and thus improve gastrointestinal condition through the increased excretion of feces containing high level of bile acids, although even excessive intake of Ashitaba for a short period of 28 d did not show any impact on the decrease in body fat or modification of lipid profiles in this study.
Angelica keiskei (Ashitaba) is a perennial plant belonging to the Umbelliferae family, which grows naturally in the Izu islands and the Izu, Bouso and Miura peninsulas of Japan ( 1 ) . The main bioactive constituents of this plant are flavonoids, coumarins and chalcones ( 2 ) . In many studies it has been reported that this plant has various physiological benefits including antibacterial ( 3 ), antitumor ( 4 , 5 ) , antiulcer ( 6 ) , and antithrombotic activity ( 7 ) , and vasodilative action ( 8 ) . Recently, much attention has been paid to the physiological effects of Ashitaba or its chalcones, particularly for the resolution of lipodystrophy of adipose tissue, otherwise known as cellulite. Cellulite is defined as a localized metabolic disorder of the subcutaneous tissue, which provokes alteration of the female body shape ( 9 ) . The effective constituents of Ashitaba in the reduction of cellulite are thought to be chalcones and coumarins. For these reasons, a number of Ashitaba products in the form of powder or tablets are widely marketed as socalled health food for weight loss and the breakdown of cellulite in Japan.
However, to date, there is little information concerning the physiological effects of Ashitaba on body fat loss or potential cellulite breakdown and lipid metabolism including lipolysis. The relevance of the amount of chalcones contained in Ashitaba to their various effects are also unclear, although it is considered that about 200-300 mg of chalcones/100 g raw leaves are contained in the edible portion of the leaf. Moreover, absorption of Ashitaba chalcones and coumarins from the digestive tract is also not clear. Thus, much of the proposed effectiveness of Ashitaba chalcones has little scientific basis.
In this study, we focused first on the physiological impacts of dietary Ashitaba on body fat accumulation and lipid profiles in rats. In order to investigate the relationship between the amount of Ashitaba ingested and lipid profiles or body fat accumulation in rats, high fat diets containing different amounts of Ashitaba powder were fed to rats. In addition, the liver and kidney of rats were also histopathologically examined after an excessive intake of Ashitaba.
MATERIALS AND METHODS

Animals and diets.
Male Wistar rats, weighing 60-80 g, were purchased from Japan SLC (Shizuoka, Japan), and maintained under a controlled room temperature (22 Ϯ 2˚C) and lighting cycle (lighting 08:00 to 20:00 h). They were fed commercial chow (CE-2; CLEA Japan, Tokyo) for 1 wk. After the acclimation, rats were randomly divided into four groups ( n ϭ 6/group). The E-mail: jnagata@nih.go.jp experimental groups received high fat diets based on AIN-93G formula containing Ashitaba powder at 17 ( ϫ 1), 170 ( ϫ 10) or 1,700 ( ϫ 100) mg/100 g body weight, while the control group received the diet without Ashitaba powder. The daily amount of Ashitaba intake in rats was estimated on a body weight-conversion basis recommended for humans. Ashitaba powder is commercially available as a so-called functional food, which contains chalcones and dietary fiber at a concentration of approximately 318.9 mg/100 g product and 31.2 g/100 g product, respectively. The composition of this diet (g/kg) was 200 g milk casein, 100 g sucrose, 200 g soybean oil, 50 g cellulose, 35 g AIN-93G mineral mixture, 10 g AIN-93VX vitamin mixture, 3 g Lcystine, 2.5 g choline bitartrate, 0.014 g tert -butylhydroquinone and ␣ -corn starch to 1,000 g. All diets contained 0.5% cholesterol and 0.125% sodium cholate. Animals were housed individually and fed each experimental diet ad libitum for 28 d. At the end of the experimental period, after overnight fasting, rats were anesthetized and sacrificed for analysis. The care and use of laboratory animals were in accordance with the guidelines laid down by Incorporated Administrative Agency, National Institute of Health and Nutrition.
Blood sample collection and chemical analysis. Blood samples were obtained from the abdominal aorta, and centrifuged at 3,000 rpm for 15 min. Sera were stored at Ϫ 80˚C until analysis. Serum lipids, indices of liver function and the other biochemical parameters were enzymatically analyzed using an Auto Analyzer (Olympus AU5232, Tokyo, Japan)
Analysis of liver lipids. The liver was excised from each rat, weighed and stored at Ϫ 80˚C until analysis. Liver lipids were extracted with chloroform-methanol (2:1 (v/v)) as described by Folch et al. ( 10 ) . Liver cholesterol and triacylglycerol concentrations were determined using a Wako enzyme assay kit (Cholesterol Etest and Triglyceride E-test Wako, Osaka, Japan) as described elsewhere, with minor modifications ( 11 ) .
Analysis of fecal bile acids. Total fecal bile acids were extracted with ethanol at 70˚C for 1 h, and analyzed enzymatically by a modification of the method of Eaton and Klassen ( 12 ) . The standard used for this assay was cholic acid.
Histopathological examination. The livers and kidneys were obtained from the rats fed the control and ϫ 100 Ashitaba diets, fixed with 10% formaldehyde solution in phosphate-buffered saline (pH 7.4) and embedded in paraffin. Paraffin-embedded specimens were prepared, and stained with hematoxylin and eosin. These samples were observed by optical microscope.
Statistical analysis. The data presented are the means Ϯ SE (standard error of the mean). Statistical significance of any differences was evaluated by one-way ANOVA followed by Fisher's PLSD test. Differences at p Ͻ 0.05 were considered to be significant.
RESULTS
Body weight gain, food intake and relative organ weights of rats fed experimental diets
Body weight gain, food intake and relative organ weights of rats fed experimental diets are shown in Table 1 . No significant differences were observed in body weight gain, or relative weights of liver, kidney, testis or epididymal adipose tissue between any of the treatment groups at the end of the feeding period. Food intake of rats fed the experimental diets tended to increase in an Ashitaba dose-dependent manner. In particular, the food intake of the ϫ 100 Ashitaba group was significantly higher ( p Ͻ 0.05) than those of the control and ϫ 1 groups. The relative spleen weight of the ϫ 100 Ashitaba group was significantly lower ( p Ͻ 0.05) than those of the control and ϫ 1 groups. However, the perirenal adipose tissue weight of the ϫ 10 Ashitaba group was significantly higher ( p Ͻ 0.05) than that of the control group.
Serum and liver lipid profiles
Serum triacylglycerol concentration of rats fed the ϫ 100 Ashitaba diets was significantly higher ( p Ͻ 0.05) than that of the ϫ 1 group although the Ashitaba intake did not affect the serum total and high-density lipoprotein (HDL) cholesterol concentrations. Moreover, the Ashitaba intakes did not affect the liver cholesterol or triacylglycerol concentrations in rats fed diets containing various amounts of Ashitaba (Table 2) . 
Serum biochemical parameters
There were no significant differences in serum protein concentrations (total protein, albumin and the ratio of albumin to globulin), indices of renal function (creatinine clearance and urea nitrogen) or blood glucose concentrations between any of the treatment groups. Indices of liver function as judged by aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) tended to decrease in response to an increase of Ashitaba ingestion. Serum ALT in the ϫ 100 Ashitaba group was significantly lower ( p Ͻ 0.05) than those of the ϫ 1 and ϫ 10 groups, and serum ALP in the ϫ 10 and ϫ 100 groups were significantly lower ( p Ͻ 0.05) than that of the ϫ1 group (Table 3) . Figure 1 shows the fecal weight and fecal bile acid level of rats fed the experimental diets. Fecal weight and bile acid level of rats fed Ashitaba-containing diets increased in a dose-dependent manner. Fecal weight of the ϫ100 group was significantly higher than those of the other groups. Similarly, the fecal bile acid levels of the ϫ10 and ϫ100 groups were also significantly higher (pϽ0.05) than those of the control and ϫ1 groups. Fecal weight and bile acid level of rats fed the ϫ100 Ashitaba-containing diet was approximately 1.6-fold higher than the control group.
Fecal weight and bile acid excretion
Histopathological examinations
Lipid droplet depositions and infiltrations of eosinophilic granules were observed throughout the rat liver and kidney of all the groups. The livers from rats fed the control diet accumulated lipid droplets in the peripheral area of the hepatic lobulus, while the livers of rats fed the ϫ100 Ashitaba diet showed deposition of lipid droplets in the hepatic centrolobular area. In addition, infiltration of eosinophilic granules in the renal tubule epithelium was observed in all the samples. However, there were no significant differences in the severity of lipid depositions in the liver or infiltrations of eosinophilic granules in the renal tubules between any of the treatment groups (data not shown).
DISCUSSION
In the present study, the large and excessive intakes of Ashitaba significantly increased fecal weights and fecal bile acid levels in rats, but the serum triacylglycerol concentration of rats fed the excessive Ashitaba diet was significantly increased. In addition, no significant impacts of Ashitaba intake were observed in the body weight gain, adipose tissue weights or liver lipid concen- trations. However, the excessive Ashitaba intake did not appear to have adverse effects on hepatic or renal functions of rats as estimated by serum biochemical indices and histopathological examinations. Cellulite is essentially an alteration to the topography of the skin that occurs mainly in the pelvic region, lower limbs and abdomens of women (13) . The hypertrophy and hyperplasia observed in cellulite appear to be responsible for hypothermia, which is a typical metabolic feature of cellulite, caused by stasis. Thus, cellulite has several structural alterations in the dermis, in the microcirculation and within adipocytes.
The physiological function of Ashitaba is thought to be ascribed to the vasodilation caused by its chalcones such as xanthoangerol, xanthoangerol E and 4-hydroxyderricin as active components (8, 14) . Ashitaba intake is, therefore, expected to improve the impaired circulatory system of the subcutaneous tissue. These effects contribute to the elimination of cellulite and are advocated as it is effective for weight loss. Thus, a number of Ashitaba products are marketed extensively as a socalled health food in Japan as if the physiological functions of Ashitaba are connected with the eradication of hypodermic cellulite. However, the effects of Ashitaba on cellulite, and the mechanisms involved, have not yet been elucidated scientifically.
From many previous investigations, the weight loss thorough metabolic changes such as an increase in lipolysis and a decrease in lipogenesis is considered to be necessary to suppress the hypertrophy and/or hyperplasia of adipocytes. For instance, an increase in ␤-oxidation of fatty acids induces not only a decrease in serum and liver lipid levels but also a mobilization of fatty acids from body fats (15, 16) . If fatty acids are mobilized from the body-fat mass and utilized for energy production, body-fat mass will decrease accordingly. Unexpectedly, however, the present data did not show a significant decrease in the serum triacylglycerol concentration, body weight or fat mass of rats fed Ashitaba diets. These observations agree, in part, with those of Ogawa et al. (17) , who also showed that the serum lipid levels in SHRSP rats were elevated after treatment with Ashitaba extract. Moreover, they reported that mRNA expression of hepatic enzymes involved in triacylglycerol metabolism was not affected by Ashitaba ingestion. Thus, it is unlikely that Ashitaba intake may directly affects lipid metabolism such as an increase in fatty acid catabolism though ␤-oxidation in rats. Therefore, many questions remain to be answered about physiological effects of Ashitaba intake on lipolysis of adipocytes. In contrast, we may have to pay attention to the increase in serum triacylglycerol concentrations by the overconsumption of Ashitaba because Ogawa et al. (17) also reported a similar observation. Thus, further detailed examinations on the relationship between the intake of Ashitaba chalcones and the changes in serum triacylglycerol concentration will be needed.
It is noteworthy in the present results that the significant excretions of fecal bile acids were observed in response to an increase of Ashitaba intake, although serum lipid levels were not influenced. These observations were thought to be due to the rich dietary fiber in Ashitaba. The increased bile acid excretion is expected to promote bile acid synthesis from cholesterol through a decreased feedback inhibition of cholesterol 7␣-hydroxylase, which is considered to catalyze the ratelimiting step in the biosynthesis of bile acids. Consequently, increased bile acid excretion results in the decreased serum cholesterol concentration in the long run. In this short-term study, however, we could not observe such a relationship.
In general, dietary fiber has various physiological functions and is helpful to those with life-style related diseases (18) . Therefore, diets rich in dietary fiber may contribute not only to ameliorate lipid metabolism but also to improve gastrointestinal condition as pre-biotics (19) as well as to prevent colorectal cancer and cardiovascular diseases (20, 21) . Ashitaba is rich in dietary fiber and thus, may be effective to prevent diseases involved in the digestive tract.
The results obtained here show that Ashitaba intake promotes excretion of both feces and bile acids, although there were no significant influences on the lipid metabolism or body fat accumulations in rats. Therefore regular daily intake of Ashitaba products may keep gastrointestinal system healthy. In addition, even excess intake of Ashitaba for a short period did not appear to have any adverse effect on hepatic or renal functions.
